Oncology News and Research

RSS
Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron reports total revenues of $304 million for second quarter 2012

EntreMed commences ENMD-2076 Phase 2 study in triple-negative breast cancer

EntreMed commences ENMD-2076 Phase 2 study in triple-negative breast cancer

WASC accredits Cedars-Sinai PhD program in biomedical sciences and translational medicine

WASC accredits Cedars-Sinai PhD program in biomedical sciences and translational medicine

Roche now offers expanded portfolio of blood screening solutions

Roche now offers expanded portfolio of blood screening solutions

NBTI participates in ICT-107 phase II trial for glioblastoma multiforme

NBTI participates in ICT-107 phase II trial for glioblastoma multiforme

Sunbed users at a 20% increased relative risk of skin cancer

Sunbed users at a 20% increased relative risk of skin cancer

RhoC gene promotes breast cancer stem cell progression

RhoC gene promotes breast cancer stem cell progression

Aeterna Zentaris files request with FDA for Fast Track designation for AEZS-130

Aeterna Zentaris files request with FDA for Fast Track designation for AEZS-130

Merck, Chimerix sign license agreement for CMX157 to treat HIV infection

Merck, Chimerix sign license agreement for CMX157 to treat HIV infection

Penn expert can offer commentary on provision of human milk during World Breastfeeding Week

Penn expert can offer commentary on provision of human milk during World Breastfeeding Week

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Walk-12 test identifies poststroke perceived limitations

Walk-12 test identifies poststroke perceived limitations

Human brown fat may actually be beige

Human brown fat may actually be beige

Central mechanism would remove physician from assisted-dying process

Central mechanism would remove physician from assisted-dying process

Bioniche receives U.S. and Canadian approval for first of two canine oncology products

Bioniche receives U.S. and Canadian approval for first of two canine oncology products

Cerulean commences dosing in CRLX101 Phase 2 study for ovarian cancer

Cerulean commences dosing in CRLX101 Phase 2 study for ovarian cancer

PTC Therapeutics completes $30M financing

PTC Therapeutics completes $30M financing

NSCLC survival increase 'an artifact of PET assessment'

NSCLC survival increase 'an artifact of PET assessment'

Aging women show nonlinear declines in fitness, activity levels

Aging women show nonlinear declines in fitness, activity levels

Physician-targeted intervention could reduce self-harm risk in elderly

Physician-targeted intervention could reduce self-harm risk in elderly

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.